StockNews downgraded Pacific Biosciences of California (PACB) to 'Sell' due to weak financials.
StockNews.com downgraded Pacific Biosciences of California (PACB) to a 'Sell' rating, citing weak financials with a negative net margin of 152.97% and negative return on equity of 40.23%. The biotech firm's market capitalization is at $415.32 million, and insiders have been selling shares, with some notable transactions. The average rating for PACB is 'Hold' with a consensus price target of $7.77.
April 21, 2024
4 Articles